FATE Stock — Fate Therapeutics Inc

Fate Therapeutics Inc (FATE)

Updated October 16, 2026.

FATE is a Stock. Total return is -73.0% over the past 13 years, 533.7 points behind SPY at 460.7%.

Fate Therapeutics is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies, primarily chimeric antigen receptor (CAR)-targeted NK and T-cell treatments for cancer and autoimmune disorders. The company does not currently distribute dividends. The company is headquartered in San Diego, California, and appeals primarily to investors seeking exposure to early-stage biotech innovation rather than income-focused portfolios.

FATE performance versus SPY

Price and return data through 2026-10-16.

Total return is -73.0% over the past 13 years, 533.7 points behind SPY at 460.7%. Over the past year its total return — price change plus distributions reinvested — is 16.2%. Its deepest 1-year drawdown was 42.4%.

FATE key facts

Asset type

Stock

Asset class

Equity

Inception date

10/01/2013

Distribution frequency

None

Last close

$1.79 (as of 2026-10-16)

Market cap

$214,478,720

Average volume

1383981.0

Beta

2.528

Payout ratio

0.0%

EPS

$-1.05

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

FATE risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 42.4%.

Who may consider FATE — and who may not

It is a weaker fit for investors who need monthly cash flow (FATE does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on FATE

• All tickers starting with F

Tagged: Healthcare.

Frequently asked questions